Amgen (AMGN) Intangibles (2009 - 2026)
Amgen (AMGN) posted quarterly Intangibles of $21.4 billion for Q1 2026, up 345.4% year-over-year from $4.8 billion in Q1 2025, and down 4.03% on a QoQ basis from $22.3 billion in Q4 2025.
Amgen (AMGN) Intangibles (2009 - 2026) Analysis & Trends
Amgen (AMGN) has reported Intangibles for 18 consecutive years, with $21.4 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Intangibles rose 345.4% year-over-year to $21.4 billion; the TTM figure through Mar 2026 stood at $21.4 billion (up 345.4% YoY), while the FY2025 annual figure was $22.3 billion, down 19.58% from the prior year.
- Intangibles came in at $21.4 billion for Q1 2026 at Amgen, down from $22.3 billion in the prior quarter.
- The five-year high for Intangibles was $32.6 billion in Q4 2023, with the low at $350.0 million in Q2 2025.
- Average Intangibles over 5 years is $19.0 billion, with a median of $16.1 billion recorded in 2022.
- Across the five-year window, Intangibles slumped 98.84% in 2025 and soared 345.4% in 2026, its largest moves.
- Year by year, Intangibles stood at $16.1 billion in 2022, then surged by 102.99% to $32.6 billion in 2023, then decreased by 15.14% to $27.7 billion in 2024, then retreated by 19.58% to $22.3 billion in 2025, then dropped by 4.03% to $21.4 billion in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $21.4 billion, $22.3 billion, and $23.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 49.06 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 50.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 36.91 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 11.30 Bn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 9.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.38 Bn |
| Dec 31, 2025 | 22.28 Bn |
| Sep 30, 2025 | 23.14 Bn |
| Jun 30, 2025 | 350.00 Mn |
| Mar 31, 2025 | 4.80 Bn |
| Dec 31, 2024 | 27.70 Bn |
| Sep 30, 2024 | 28.92 Bn |
| Jun 30, 2024 | 30.17 Bn |
| Mar 31, 2024 | 31.37 Bn |
| Dec 31, 2023 | 32.64 Bn |
| Sep 30, 2023 | 13.15 Bn |
| Jun 30, 2023 | 14.63 Bn |
| Mar 31, 2023 | 15.39 Bn |
| Dec 31, 2022 | 16.08 Bn |
| Sep 30, 2022 | 13.27 Bn |
| Jun 30, 2022 | 13.93 Bn |
| Mar 31, 2022 | 14.57 Bn |
| Dec 31, 2021 | 15.18 Bn |
| Sep 30, 2021 | 14.66 Bn |
| Jun 30, 2021 | 15.31 Bn |